menu
    • menu
    [{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Artemether","moa":"||Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Medicines for Malaria Venture","sponsor":"SGS Life Sciences | Institute of Tropical Medicine, Belgium | Swiss BioQuant | PrimeVigilance Ltd | Sanaria | IQVIA | FGK Representative Service","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Medicines for Malaria Venture","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicines for Malaria Venture \/ SGS Life Sciences | Institute of Tropical Medicine, Belgium | Swiss BioQuant | PrimeVigilance Ltd | Sanaria | IQVIA | FGK Representative Service","highestDevelopmentStatusID":"6","companyTruncated":"Medicines for Malaria Venture \/ SGS Life Sciences | Institute of Tropical Medicine, Belgium | Swiss BioQuant | PrimeVigilance Ltd | Sanaria | IQVIA | FGK Representative Service"},{"orgOrder":0,"company":"Universidad Nacional de Colombia","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Universidad Nacional de Colombia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidad Nacional de Colombia \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Universidad Nacional de Colombia \/ Sanofi"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"GHIT Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Artemether","moa":"||Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fosun Pharmaceutical \/ GHIT Fund","highestDevelopmentStatusID":"10","companyTruncated":"Fosun Pharmaceutical \/ GHIT Fund"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"European & Developing Countries Clinical Trials Partnership | Medicines for Malaria Venture | Groupe de Recherche Action en Sante | Institut de Recherche en Sciences de la Sante","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ European & Developing Countries Clinical Trials Partnership | Medicines for Malaria Venture | Groupe de Recherche Action en Sante | Institut de Recherche en Sciences de la Sante","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ European & Developing Countries Clinical Trials Partnership | Medicines for Malaria Venture | Groupe de Recherche Action en Sante | Institut de Recherche en Sciences de la Sante"},{"orgOrder":0,"company":"Medicines for Malaria Venture","sponsor":"Southern Star Research | Nucleus Network","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Medicines for Malaria Venture","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicines for Malaria Venture \/ Southern Star Research | Nucleus Network","highestDevelopmentStatusID":"6","companyTruncated":"Medicines for Malaria Venture \/ Southern Star Research | Nucleus Network"},{"orgOrder":0,"company":"Centro de Investigacao em Saude de Manhica","sponsor":"World Health Organization (Mozambique) | National Malaria Control Program, Mozambique | Instituto Nacional de Sa\u00fade, Mozambique","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Centro de Investigacao em Saude de Manhica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centro de Investigacao em Saude de Manhica \/ World Health Organization (Mozambique) | National Malaria Control Program, Mozambique | Instituto Nacional de Sa\u00fade, Mozambique","highestDevelopmentStatusID":"1","companyTruncated":"Centro de Investigacao em Saude de Manhica \/ World Health Organization (Mozambique) | National Malaria Control Program, Mozambique | Instituto Nacional de Sa\u00fade, Mozambique"}]

    Find Clinical Drug Pipeline Developments & Deals for Malartem

    Menu

    Malartem

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Centro de Investigacao em Saude de Manhica

                            Country arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Centro de Investigacao em Saude de Manhica

                            Country arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Artemether

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : World Health Organization (Mozambique) | National Malaria Control Program, Mozambique | Instituto Nacional de Saúde, Mozambique

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Artemether-Lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Childre...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 14, 2025

                            Lead Product(s) : Artemether

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : World Health Organization (Mozambique) | National Malaria Control Program, Mozambique | Instituto Nacional de Saúde, Mozambique

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Artemether,Lumefantrine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Novartis and Medicines for Malaria Venture Report Positive Data for Malaria in Babies

                            Details : Coartem® (artemether-lumefantrine) a novel formulation which is being developed forthe treatment of babies weighing less than 5kg with malaria.

                            Product Name : Coartem

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 23, 2024

                            Lead Product(s) : Artemether,Lumefantrine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Fosun Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Fosun Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Artemether,Amodiaquine,Lumefantrine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : GHIT Fund

                            Deal Size : $3.3 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for a New Antimalarial Drug Receives 500 M...

                            Details : The financing will be used for a clinical phase III trial for a fixed-dose combination of artemether-lumefantrine-amodiaquine drug (three existing antimalarial drugs already developed, marketed and sold) against malaria.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 13, 2023

                            Lead Product(s) : Artemether,Amodiaquine,Lumefantrine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : GHIT Fund

                            Deal Size : $3.3 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Universidad Nacional de Colombia

                            Country arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Universidad Nacional de Colombia

                            Country arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Artemether

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Assessment of the Therapeutic Efficacy and Tolerability of the Artesunate/Amodiaquina Combination and Artemeth...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 07, 2021

                            Lead Product(s) : Artemether

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Medicines for Malaria Venture

                            Country arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Medicines for Malaria Venture

                            Country arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Artemether

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Southern Star Research | Nucleus Network

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Ruxolitinib With Artemether-lumefa...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 02, 2020

                            Lead Product(s) : Artemether

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Southern Star Research | Nucleus Network

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Medicines for Malaria Venture

                            Country arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Medicines for Malaria Venture

                            Country arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Artemether

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : SGS Life Sciences | Institute of Tropical Medicine, Belgium | Swiss BioQuant | PrimeVigilance Ltd | Sanaria | IQVIA | FGK Representative Service

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 17, 2020

                            Lead Product(s) : Artemether

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : SGS Life Sciences | Institute of Tropical Medicine, Belgium | Swiss BioQuant | PrimeVigilance Ltd | Sanaria | IQVIA | FGK Representative Service

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Artemether

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : European & Developing Countries Clinical Trials Partnership | Medicines for Malaria Venture | Groupe de Recherche Action en Sante | Institut de Recherche en Sciences de la Sante

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Inf...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 09, 2020

                            Lead Product(s) : Artemether

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : European & Developing Countries Clinical Trials Partnership | Medicines for Malaria Venture | Groupe de Recherche Action en Sante | Institut de Recherche en Sciences de la Sante

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Neopharma

                            U.A.E arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Neopharma

                            U.A.E arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Artemether

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Parexel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrou...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 16, 2019

                            Lead Product(s) : Artemether

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Parexel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            University of California, San Francisco

                            Country arrow
                            CPHI Shenzhen
                            Not Confirmed

                            University of California, San Francisco

                            Country arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Artemether

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Center for Malariology, Parasitology, and Entomology | The National Institute of Public Health | Health Poverty Action

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 21, 2018

                            Lead Product(s) : Artemether

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Center for Malariology, Parasitology, and Entomology | The National Institute of Public Health | Health Poverty Action

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Professor Anders Björkman

                            Country arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Professor Anders Björkman

                            Country arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Artemether

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Zanzibar Malaria Control Programme | World Health Organization

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 05, 2018

                            Lead Product(s) : Artemether

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Zanzibar Malaria Control Programme | World Health Organization

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth